Monoclonal Antibodies and Immuno-PET Imaging: An Overview

Creative Commons License

Sarcan E. T., Özer A. Y.

FABAD JOURNAL OF PHARMACEUTICAL SCIENCES, vol.48, no.1, pp.165-182, 2023 (Scopus) identifier identifier


Radiopharmaceuticals are radioactive medicines used for imaging and/or therapeutic purposes, consisting of radionuclidic and pharmaceutical parts. While Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) methods are commonly used for imaging purposes, the immuno- PET imaging method has gained popularity recently. Immuno- PET imaging method is a combination of PET radionuclides and biomolecules, especially monoclonal antibodies (mAb), proteins, peptides, which are frequently used for the imaging of different types of cancer. Radionuclides with long half-lives are generally used in immuno-PET imaging. Long biological half-lives of mAbs are the most important reason to be preferred for immuno-PET imaging. Today, Zirconium-89 (Zr-89), Iodine-124 (I-124) with long half- lives and Copper-64 (Cu-64) and Yttrium-86 (Y-86) radionuclides with relatively long half-lives are preferred in immuno-PET imaging. In this article, preclinical and clinical studies of Zr-89, Cu-64, I-124 and Y-86-labeled mAbs with a long half-lives were reviewed. Also, these 4 radionuclides, which are frequently used in the labelling of biomolecules (particularly mAbs) are compared.